Affordable Access

[Sexual dysfunction secondary to SSRIs. A comparative analysis in 308 patients].

Authors
  • Montejo, A I
  • Llorca, G
  • Izquierdo, J A
  • Ledesma, A
  • Bousoño, M
  • Calcedo, A
  • Carrasco, J L
  • Daniel, E
  • de Dios, A
  • de la Gándara, J
  • Derecho, J
  • Franco, M
  • Gómez, M J
  • Macías, J A
  • Martín, T
  • Pérez, V
  • Sánchez, J M
  • Sánchez, S
  • Vicens, E
Type
Published Article
Journal
Actas luso-españolas de neurología, psiquiatría y ciencias afines
Publication Date
Jan 01, 1996
Volume
24
Issue
6
Pages
311–321
Identifiers
PMID: 9054202
Source
Medline
License
Unknown

Abstract

There is a significant increase in the incidence of SD when the physicians ask the patients direct questions (55.29%) versus spontaneous SD reported (14.2%). There are some significant differences among different SSRIs paroxetine provoked more delay of orgasm/ejaculation and more impotence than fluvoxamine, fluoxetine and sertraline (Chi square p < 0.05). Only 22.6% of the patients had a good tolerance about their sexual dysfunction. SD has positive correlation with the dose. The patients experienced substantial improvement in sexual function when the dose was diminished or the drug was withdrawn. Men showed more incidence of sexual dysfunction than women but women's sexual dysfunction was more intense than men. Seven of nine patients (77.7%) experienced total improvement when the treatment was changed to Moclobemide (450 mg/day) and two of four patients (50%) improved when treatment was changed to Amineptine.

Report this publication

Statistics

Seen <100 times